Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
Public ClinicalTrials.gov record NCT00655252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Study identification
- NCT ID
- NCT00655252
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Everolimus Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Aug 18, 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands oncology Group, PA | Springdale | Arkansas | 72764 | — |
| University of Colorado Health Sciences Center/Anschutz Pavillion | Aurora | Colorado | 12801 | — |
| Cancer Centers of Florida, P.A. | Ocoee | Florida | 34761 | — |
| MD Anderson Cancer Center - Orlando | Orlando | Florida | 32806 | — |
| Indiana University Cancer center | Indianapolis | Indiana | 46202 | — |
| The Cancer Institute, St. Joseph Medical Center | Towson | Maryland | 21209 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | — |
| Heartland Hematology-Oncology Associates, Inc. | Kansas City | Missouri | 64118 | — |
| Washington University/Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Blumenthal Cancer Center/Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Cliveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Cleo Craig Memorial Cancer & Research Clinic | Lawton | Oklahoma | 73505 | — |
| Cancer centers of the Carolinas | Greenville | South Carolina | 29615 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00655252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00655252 live on ClinicalTrials.gov.